Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Recent news and posts

Tags

Use tags to find relevant records
3D printed implants
Ablation methods
Allogeneic mesenchymal stem cells
Ambulatory ECG monitoring
Andalusia
Aortic abdominal aneurysm
Aortic root replacement
Arthroplasty
Arthroscopy
Artificial intelligence (AI)
Assisted ventilation
Atherectomy
Austria
Autologous chondrocyte implantation
Automated external defibrillator
AV fistula
AV graft
Balloon kyphoplasty
Bariatric surgery
Baroreflex activation therapy
Barrett’s oesophagus
Belgium
Benign prostatic hyperplasia
Biopsy
Bioresorbable stents
Bone Conductive Hearing Device
Breast reconstruction
Bronchial thermoplasty
Burns
Caesarean section
Cancer
Capsule endoscopy
Carbon ion therapy
Cardiac ablation
Cardiac computer tomography
Cardiac pacemaker
Cardiac resynchronization therapy
Cardiac Resynchronization Therapy Defibrillator (CRT-D)
Cardiovascular devices
Cardiovascular procedures
Carotid endarterectomy
Case study
Cataract
Cell therapy
Cholecystectomy
Chronic obstructive pulmonary disease
Chronic wounds
Clinical guidelines
Cochlear implants
Commissioning
Computed tomography
Conditional reimbursement
Connected medical devices
Continuous glucose monitoring (CGM)
Coronary interventions
Coronary percutaneous revascularization procedures
See all tags

Additional subsidy round for Evaluation Research was opened in the Netherlands

In June 2019, the Dutch National Health Care Institute (Zorginstituut Nederland, ZIN) jointly with the Netherlands Organization for Health Research and Development (Nederlandse organisatie voor gezondheidsonderzoek en zorginnovatie, ZonMw) launched a program for evaluation and appropriate use of care (Zorgevaluatie en Gepast Gebruik, ZE&GG) by connecting all partners to a cycle of scheduling, evaluating and implementing knowledge about what good care is with further effective use of the available public funds as well as medical and nursing care available to everyone.

In October 2019, an additional subsidy round for Evaluation Research was opened on behalf of the ZE&GG program for diagnostics and follow-up/aftercare within both medical and nursing care. The submission deadline is on the 28th of November 2019.

See full details in Dutch here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

Tags
Netherlands
Funding
Innovation funding
Innovative payment schemes

The latest related news

22
Feb 2024

NHS Cancer Programme Innovation Open Call 3 announced in England

On January 26, 2024, NHS England announced the third round of the Innovation Open Call, funded by the NHS Cancer Programme. All types of late-stage innovations aimed at early detection and diagnosis of cancer are eligible, including medical devices, in-vitro diagnostics, digital health solutions, and AI. Awarded projects will be 100% funded up to the total value of £4 million to produce and evaluate evidence in a real-world setting, supporting adoption and spread by providers, commissioners, and regulators. The application submission will be open on April 8, 2024.
Read more
09
Feb 2024

New national catalog for genetic tests released in Spain

On January 23, 2024, the Ministry of Health introduced a new national catalog, which guarantees the Spanish population's genetic tests nationwide. Currently, the catalog includes 672 tests in eight disease areas, including adult and pediatric oncohematology, pharmacogenomics, hereditary metabolic and mitochondrial diseases, and others. Twelve more disease areas are expected to be added in 2024.
Read more